Level Four Advisory Services’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
CM
GGHC
FP
Level Four Advisory Services's DNLI Position: Q1 2021 in Review
Level Four Advisory Services sold out of Denali Therapeutics (DNLI) in Q1 2021, closing a stake of 4,477 shares — an estimated $375K sold.
Level Four Advisory Services first reported a position in DNLI in Q4 2020 and held it in 1 quarter. The position peaked at $375K in Q4 2020. 216 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.
- Level Four Advisory Services reported no remaining Denali Therapeutics position as of Q1 2021 after selling out during the quarter.
- Level Four Advisory Services sold 4,477 Denali Therapeutics shares in Q1 2021, an estimated $375K.
- Level Four Advisory Services first reported a position in Denali Therapeutics in Q4 2020 and held it in 1 quarter.
- Level Four Advisory Services's Denali Therapeutics position peaked at $375K in Q4 2020.
- 216 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.
Based on Level Four Advisory Services's 13F filing for Q1 2021, filed 10 May 2021.